MD HB962 | 2019 | Regular Session
Status
Spectrum: Partisan Bill (Democrat 4-0)
Status: Engrossed on April 4 2019 - 50% progression, died in committee
Action: 2019-04-08 - Rereferred to Finance
Pending: Senate Finance Committee
Text: Latest bill text (Engrossed) [PDF]
Status: Engrossed on April 4 2019 - 50% progression, died in committee
Action: 2019-04-08 - Rereferred to Finance
Pending: Senate Finance Committee
Text: Latest bill text (Engrossed) [PDF]
Summary
Requiring the Maryland Medical Assistance Program, subject to the limitations of the State budget, to provide coverage for any medically appropriate drugs that are approved by the United States Food and Drug Administration for the treatment of hepatitis C, regardless of the fibrosis score, and that are determined to be medically necessary.
Title
Maryland Medical Assistance Program - Coverage - Hepatitis C Drugs
Sponsors
Roll Calls
2019-03-27 - House - House Floor - Third Reading Passed (132-0) (Y: 132 N: 0 NV: 6 Abs: 3) [PASS]
History
| Date | Chamber | Action |
|---|---|---|
| 2019-04-08 | Senate | Rereferred to Finance |
| 2019-04-05 | Senate | First Reading Senate Rules |
| 2019-04-04 | House | Third Reading Passed (132-0) |
| 2019-04-04 | House | Second Reading Passed with Amendments |
| 2019-04-04 | House | Favorable with Amendments {396081/1 Report Adopted |
| 2019-04-04 | House | Favorable with Amendments Report by Health and Government Operations |
| 2019-02-19 | House | Hearing 3/14 at 1:00 p.m. |
| 2019-02-08 | House | First Reading Health and Government Operations |
Subjects
Diseases
Drugs
Health Insurance
Medical Assistance
Medical Treatments
Patients
Physicians
Public Health
Records
Drugs
Health Insurance
Medical Assistance
Medical Treatments
Patients
Physicians
Public Health
Records
